Close

Alnylam (ALNY) Offers New Pre-Clinical Data on RNAi Therapeutic Program in Hemophilia

July 11, 2012 8:04 AM EDT Send to a Friend
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login